Trevena

In 2008, the company raised $25 Million in a Series A financing round led by Alta Partners, Polaris Ventures, New Enterprise Associates, Healthcare Ventures, and Yasuda Economic Development Corporation.In early 2009, Trevena entered into a collaborative agreement with Ligand Pharmaceuticals to identify biased ligands at numerous GPCRs from a large, diverse chemical library. Later that year, Trevena received a competitively awarded American Recovery and Reinvestment Act Grand Opportunities Grant, spanning two years and funding US$7.65 million of research. The company has disclosed specific interests in the mu Opioid receptor and kappa Opioid receptor. The company raised an additional US$35 million in a B round of venture financing in the summer of 2010. In 2011, Treveva received another NIH grant as part of the NIH Blueprint Neurotherapeutics Network, potentially worth up to $10M USD, to support preclinical development of a delta opioid receptor biased ligand for major depressive disorder. Trevena has received funding from the Michael J. Fox Foundation to explore the potential for delta opioid receptor biased ligands to treat Parkinson's disease.Trevena's initial public offering was on January 30, 2014.